GatewaySeq NGS Panel with Interpretation: Coming Soon

Test DetailsA tumor-only, high coverage targeted next generation sequencing assay for the identification of gene mutations, copy number alterations, microsatellite instability, tumor mutational burden, and gene fusions. The intended use of GatewaySeq is to provide a targeted genomic assessment of formalin or alcohol-fixed, paraffin-embedded surgical and cytological specimens from patients with solid tumors at initial diagnosis, relapse, or metastasis. GatewaySeq serves to identify the most common clinically significant mutations as an initial assay, and does not preclude additional, more comprehensive genomic profiling by other commercially available assays.

GatewaySeq is not intended for use in patients without morphologically apparent disease, to determine site of origin in cancer of unknown primary, or to monitor disease in cell-free DNA.

Note: GatewaySeq testing will be resulted with a professional interpretation. If providers wish to opt out of the interpretation, please notate that in the “comments” section of the order.
Relevant Condition(s)GatewaySeq can be applied to, but is not limited to, cancers of the breast, gastrointestinal tract, lung, skin, thyroid, genitourinary tract, gynecologic tract, hepatobiliary tract, bone and soft tissue, brain, and for lymphomas.
Target(s)Gene mutations (single nucleotide variants and indels in exonic regions) for 133 genes: AR, ARAF, AKT1, ALK, APC, ARID1A, ATM, ATRX, B2M, BAP1, BARD1, BCL10, BCL2, BRIP1, BRAF, BRCA1, BRCA2, BTK, CCND1, CARD11, CD79B, CDH1, CCND3, CCNE1, CDK12, CDK4, CDKN2A, CDKN2B, CHEK1, CHEK2, CIC, CREBBP, DICER1, CTNNB1, CXCR4, DNMT3A, EGFR, EIF1AX, EP300, ERBB2, EZH2, ESR1, ETV6, FANCA, FANCL, FGFR1, FGFR2, FGFR3, FOXO1, FUBP1, GNA11, H3F3A, GNA13, GNAQ, HIST1H1E, HIST1H3B, HIST1H3C, HRAS, ID3, IDH1, IDH2, ITPKB, KIT, KLF2, KMT2D, KRAS, MAP2K1, MLH1, MDM2, MEF2B, MET (includes MET exon 14 skipping variants), MYC, MSH2, MSH6, MYCN, NFKBIE, MYD88, NF1, NF2, NTRK1, NTRK2, NTRK3, NOTCH1, NOTCH2, NRAS, PAX8, PALB2, PIK3CA, PDGFRA, PMS2, POLD1, POLE, PIM1, PLCG2, PTCH1, PTEN, PTPRD, RAD51B, RAD51C, RAD51D, RAF1, RB1, RRAGC, RET, RHOA, ROS1, SDHC, SDHD, RSPO3, SDHA, SDHB, SMAD4, SMARCA4, SF3B1, SGK1, SMARCB1, STK11, STAT3, STAT5B, STAT6, TERT (includes TERT promoter variants), TCF3, TP53, TET2, TFE3, TFEB, TNFAIP3, TNFRSF14, TRAF7, TSC1, TSC2, VHL, XPO1

Copy number alterations: CCND1, CCNE1, CDKN2A/B, EGFR, KRAS, MDM2, MET, MYC, PDGFRA, PTEN, TP53

Structural variants (gene fusions and large deletions): ALK, CD74, EGFR, ETV6, FGFR2, NTRK1, RET, ROS1

Microsatellite instability
Tumor mutational burden
MethodologyNext-Generation Sequencing using Unique Molecular Identifiers (UMIs)
FrequencyTesting is set up weekly.
Turnaround TimeResults are available within approximately 10-14 business days.
Specimen RequirementsTissue, formalin-fixed, paraffin-embedded (FFPE) or alcohol-fixed formalin embedded tissue from cell blocks.
Minimum tumor cellularity: 10%
Specimen CollectionTo be ordered on previously collected surgical and cytological specimens (pathology case number required).
Minimum Specimen VolumeTen, 10-micron sections
Storage/Transport ConditionsShip at room temperature
Unacceptable ConditionsUnacceptable specimen conditions include fresh tissue, blood or bone marrow aspirate, incorrect specimen container, or unlabeled specimen.
CPT Code(s)81445